Skip to main content
Top
Published in: PharmacoEconomics 9/2011

01-09-2011 | Original Research Article

To Fund or Not to Fund

Development of a Decision-Making Framework for the Coverage of New Health Technologies

Authors: Dr Tania Stafinski, Devidas Menon, Christopher McCabe, Donald J. Philippon

Published in: PharmacoEconomics | Issue 9/2011

Login to get access

Abstract

Background: Attempts to improve the acceptability of resource allocation decisions around new health technologies have spanned many years, fields and disciplines. Various theories of decision making have been tested and methods piloted, but, despite their availability, evidence of sustained uptake is limited. Since the challenge of determining which of many technologies to fund is one that healthcare systems have faced since their inception, an analysis of actual processes, criticisms confronted and approaches used to manage them may serve to guide the development of an ‘evidence-informed’ decisionmaking framework for improving the acceptability of decisions.
Objective: The purpose of this study was to develop a technology funding decision-making framework informed by the experiences of multiple healthcare systems and the views of senior-level decision makers in Canada.
Methods: A 1-day, facilitated workshop was held with 16 senior-level healthcare decision makers in Canada. International examples of actual technology funding decision-making processes were presented. Participants discussed key elements of these processes, debated strengths and weaknesses and highlighted unresolved challenges. The findings were used to construct a technology decision-making framework on which participant feedback was then sought. Its relevance, content, structure and feasibility were further assessed through key informant interviews with ten additional senior-level decision makers.
Results: Six main issues surrounding current processes were raised: (i) timeliness; (ii) methodological considerations; (iii) interpretations of value for money; (iv) explication of social values; (v) stakeholder engagement; and (vi) accountability for reasonableness. While no attempt was made to force consensus on what should constitute each of these, there was widespread agreement on questions that must be addressed through a robust process. These questions, grouped and ordered into three phases, became the final framework.
Conclusions: A decision-making framework informed by processes in other jurisdictions and the views of local decision makers was developed. Pilot testing underway in one Canadian jurisdiction will identify any further refinements needed to optimize its usefulness.
Literature
2.
go back to reference Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff (Millwood) 1998; 17 (5): 50–64CrossRef Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff (Millwood) 1998; 17 (5): 50–64CrossRef
3.
go back to reference Zhu K, Weyant JP. Strategic decisions of new technology adoption under asymmetric information: a game-theoretic model. Decis Sci 2003; 34 (4): 643–75CrossRef Zhu K, Weyant JP. Strategic decisions of new technology adoption under asymmetric information: a game-theoretic model. Decis Sci 2003; 34 (4): 643–75CrossRef
4.
go back to reference Robbins SP, Judge TA. Organizational behavior. 12th ed. Upper Saddle River (NJ): Pearson Prentice Hall, 2007 Robbins SP, Judge TA. Organizational behavior. 12th ed. Upper Saddle River (NJ): Pearson Prentice Hall, 2007
5.
go back to reference Cohen MD, March JG, Olsen JP. A garbage can model of organizational choice. Admin Sci Q 1972; 17 (1): 1–25CrossRef Cohen MD, March JG, Olsen JP. A garbage can model of organizational choice. Admin Sci Q 1972; 17 (1): 1–25CrossRef
7.
go back to reference O’Brien BJ, Goeree R, Gafni A, et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care 1998; 36 (3): 370–84PubMedCrossRef O’Brien BJ, Goeree R, Gafni A, et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care 1998; 36 (3): 370–84PubMedCrossRef
8.
9.
go back to reference Mitton C, Peacock S, Donaldson C, et al. Using PBMA in health care priority setting: description, challenges and experience. Appl Health Econ Health Policy 2003; 2 (3): 121–7PubMed Mitton C, Peacock S, Donaldson C, et al. Using PBMA in health care priority setting: description, challenges and experience. Appl Health Econ Health Policy 2003; 2 (3): 121–7PubMed
10.
go back to reference Farrar S, Ryan M, Ross D, et al. Using discrete choice modelling in priority setting: an application to clinical service developments. Soc Sci Med 2000; 50 (1): 63–75PubMedCrossRef Farrar S, Ryan M, Ross D, et al. Using discrete choice modelling in priority setting: an application to clinical service developments. Soc Sci Med 2000; 50 (1): 63–75PubMedCrossRef
11.
go back to reference Stafinski T, Menon D, Philippon DJ, et al. Health technology funding decision-making processes around the world: the same yet different. Pharmacoeconomics 2011; 29 (6): 475–95PubMedCrossRef Stafinski T, Menon D, Philippon DJ, et al. Health technology funding decision-making processes around the world: the same yet different. Pharmacoeconomics 2011; 29 (6): 475–95PubMedCrossRef
12.
go back to reference Simon H. Rational decision making in business organizations. Am Econ Rev 1979; 69 (4): 493–513 Simon H. Rational decision making in business organizations. Am Econ Rev 1979; 69 (4): 493–513
14.
go back to reference Simon H. Bounded rationality and organizational learning. Organization Sci 1991; 2 (1): 125–34CrossRef Simon H. Bounded rationality and organizational learning. Organization Sci 1991; 2 (1): 125–34CrossRef
15.
go back to reference Etzioni A. Mixed-scanning: a ‘third’ approach to decisionmaking. Public Adm Rev 1967; 27 (5): 385–92CrossRef Etzioni A. Mixed-scanning: a ‘third’ approach to decisionmaking. Public Adm Rev 1967; 27 (5): 385–92CrossRef
16.
go back to reference Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy 2008; 86 (2-3): 129–41PubMedCrossRef Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy 2008; 86 (2-3): 129–41PubMedCrossRef
17.
go back to reference Rocchi A, Menon D, Verma S, et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008; 11 (4): 771–83PubMedCrossRef Rocchi A, Menon D, Verma S, et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008; 11 (4): 771–83PubMedCrossRef
18.
go back to reference Milewa T. Health technology adoption and the politics of governance in the UK. Soc Sci Med 2006; 63 (12): 3102–12PubMedCrossRef Milewa T. Health technology adoption and the politics of governance in the UK. Soc Sci Med 2006; 63 (12): 3102–12PubMedCrossRef
19.
go back to reference Patten S, Mitton C, Donaldson C. From the trenches: views from decision-makers on health services priority setting. Health Serv Manage Res 2005; 18 (2): 100–8PubMedCrossRef Patten S, Mitton C, Donaldson C. From the trenches: views from decision-makers on health services priority setting. Health Serv Manage Res 2005; 18 (2): 100–8PubMedCrossRef
20.
go back to reference Sinclair S, Hagen NA, Chambers C, et al. Accounting for reasonableness: exploring the personal internal framework affecting decisions about cancer drug funding. Health Policy 2008; 86 (2-3): 381–90PubMedCrossRef Sinclair S, Hagen NA, Chambers C, et al. Accounting for reasonableness: exploring the personal internal framework affecting decisions about cancer drug funding. Health Policy 2008; 86 (2-3): 381–90PubMedCrossRef
21.
go back to reference Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ 2004; 329 (7459): 227–9PubMedCrossRef Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ 2004; 329 (7459): 227–9PubMedCrossRef
22.
go back to reference Williams I, Bryan S. Understanding the limited impact of economic evaluation in health care resource allocation: a conceptual framework. Health Policy 2007; 80 (1): 135–43PubMedCrossRef Williams I, Bryan S. Understanding the limited impact of economic evaluation in health care resource allocation: a conceptual framework. Health Policy 2007; 80 (1): 135–43PubMedCrossRef
23.
go back to reference Dolan P, Green C. Using the person trade-off approach to examine differences between individual and social values. Health Econ 1998; 7 (4): 307–12PubMedCrossRef Dolan P, Green C. Using the person trade-off approach to examine differences between individual and social values. Health Econ 1998; 7 (4): 307–12PubMedCrossRef
24.
go back to reference Sabik LM, Lie RK. Principles versus procedures in making health care coverage decisions: addressing inevitable conflicts. Theor Med Bioeth 2008; 29 (2): 73–85PubMedCrossRef Sabik LM, Lie RK. Principles versus procedures in making health care coverage decisions: addressing inevitable conflicts. Theor Med Bioeth 2008; 29 (2): 73–85PubMedCrossRef
25.
go back to reference Menon D, Stafinski T. Engaging the public in prioritysetting for health technology assessment: findings from a citizens’ jury. Health Expect 2008; 11 (3): 282–93PubMedCrossRef Menon D, Stafinski T. Engaging the public in prioritysetting for health technology assessment: findings from a citizens’ jury. Health Expect 2008; 11 (3): 282–93PubMedCrossRef
27.
go back to reference Crabtree BF, Miller WL, editors. Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage Publications, 1999 Crabtree BF, Miller WL, editors. Doing qualitative research. 2nd ed. Thousand Oaks (CA): Sage Publications, 1999
28.
go back to reference Menon D, Stafinski T, Stuart G. Access to drugs for cancer: does where you live matter? Can J Public Health 2005; 96 (6): 454–8PubMed Menon D, Stafinski T, Stuart G. Access to drugs for cancer: does where you live matter? Can J Public Health 2005; 96 (6): 454–8PubMed
33.
go back to reference Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff 1997; 26 (4): 303–50PubMedCrossRef Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff 1997; 26 (4): 303–50PubMedCrossRef
Metadata
Title
To Fund or Not to Fund
Development of a Decision-Making Framework for the Coverage of New Health Technologies
Authors
Dr Tania Stafinski
Devidas Menon
Christopher McCabe
Donald J. Philippon
Publication date
01-09-2011
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2011
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11539840-000000000-00000

Other articles of this Issue 9/2011

PharmacoEconomics 9/2011 Go to the issue

Adis Pharmacoeconomic Drug Evaluation

Cinacalcet